Creative Biolabs Enhances Anti-Glycan Antibody Discovery for Immune-Evasive Viral Threats

Creative Biolabs significantly advances its anti-glycan antibody development capabilities, addressing the formidable challenge of glycan-shielded viruses like Ebola, Marburg, dengue, and Zika. These pathogens evade immune detection via dense glycan coatings, complicating vaccine and therapeutic antibody discovery. Researchers face hurdles including complex glycosylation heterogeneity, limited glycan antigens, and low immunogenicity, hindering specific neutralizing antibody generation.

To overcome these barriers, Creative Biolabs leverages integrated glycoengineering expertise and advanced antibody screening technologies. Offering customized solutions for glycan-related antibody development, the company targets high-priority pathogens such as Ebola/Marburg and flaviviruses. Their platform integrates glycan synthesis, antigen design, hybridoma development, and high-throughput antibody characterization, accelerating novel antiviral candidate discovery.

"Glycan shields represent critical immune evasion mechanisms in virology," states a Creative Biolabs scientist. Empowering researchers to identify glycan-targeting antibodies with superior specificity, sensitivity, and translational potential is their goal. Creative Biolabs partners globally, providing end-to-end support and cutting-edge glycoimmunology and antibody engineering to combat immune-evasive viral threats effectively.